Abivax SA American Depositary Shares (ABVX)vsNovartis AG ADR (NVS)
ABVX
Abivax SA American Depositary Shares
$101.53
-3.24%
HEALTHCARE · Cap: $8.19B
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1149859% more annual revenue ($56.58B vs $4.92M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
ABVX
Avoid32
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABVX.
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.2% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 16.1x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABVX
The strongest argument for ABVX centers on Revenue Growth. Revenue growth of 35.2% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ABVX
The primary concerns for ABVX are Price/Book, EPS Growth, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
ABVX profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
ABVX is growing revenue faster at 35.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 32/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abivax SA American Depositary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies aimed at treating chronic inflammatory diseases and viral infections, with its lead candidate ABX464 currently in clinical trials for ulcerative colitis among other indications. The company distinguishes itself by utilizing a unique approach that integrates antibody-mediated therapies with proprietary compounds, addressing critical unmet medical needs in the healthcare sector. With a robust pipeline and a team of skilled scientists committed to advancing therapeutic innovation, Abivax presents an attractive investment proposition for institutional investors seeking to leverage growth opportunities within the immunotherapy landscape.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?